Pages that link to "Q28281932"
Jump to navigation
Jump to search
The following pages link to Distinct mechanism for antidepressant activity by blockade of central substance P receptors (Q28281932):
Displaying 50 items.
- Paroxetine versus other anti-depressive agents for depression (Q24197507) (← links)
- The hypocretin/orexin system (Q24537243) (← links)
- Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Q24567550) (← links)
- Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia (Q24600118) (← links)
- Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety (Q24675009) (← links)
- Psychological stress and fibromyalgia: a review of the evidence suggesting a neuroendocrine link (Q24801007) (← links)
- Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. (Q24816519) (← links)
- Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management (Q26751458) (← links)
- Biological and Pharmacological Aspects of the NK1-Receptor (Q26784074) (← links)
- The pharmacology of neurokinin receptors in addiction: prospects for therapy (Q26785438) (← links)
- Pharmacological and methodological aspects of the separation-induced vocalization test in guinea pig pups; a systematic review and meta-analysis (Q26830014) (← links)
- A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care (Q26851160) (← links)
- Pharmacological treatment of anxiety disorders: current treatments and future directions (Q26851461) (← links)
- Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner (Q27318383) (← links)
- The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment (Q28072345) (← links)
- Emerging drugs for the treatment of anxiety (Q28083141) (← links)
- Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach (Q28085005) (← links)
- New mechanisms and perspectives in nicotine withdrawal (Q28111991) (← links)
- Increased emergence of alpha activity over the left but not the right temporal lobe within a dark acoustic chamber: differential response of the left but not the right hemisphere to transcerebral magnetic fields (Q28138826) (← links)
- The tachykinin NK1 receptor in the brain: pharmacology and putative functions (Q28141864) (← links)
- NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development (Q28205016) (← links)
- Invited review: the evolution of antidepressant mechanisms (Q28241221) (← links)
- Emerging targets for antidepressant therapies (Q28247614) (← links)
- Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders (Q28253725) (← links)
- Potential therapeutic targets for neurokinin-1 receptor antagonists (Q28262693) (← links)
- Neurokinin 1 receptor antagonism as a possible therapy for alcoholism (Q28268781) (← links)
- New approaches to antidepressant drug discovery: beyond monoamines (Q28293089) (← links)
- Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea pig (Q28377533) (← links)
- Antidepressants influence somatostatin levels and receptor pharmacology in brain (Q28568340) (← links)
- Developing novel treatments for mood disorders: accelerating discovery (Q28609425) (← links)
- Novel targets for antidepressant therapies (Q28648254) (← links)
- A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults (Q28740565) (← links)
- New therapeutic targets for mood disorders (Q28743068) (← links)
- Multifunctional drugs for head injury (Q30371428) (← links)
- Involvement of midbrain tectum neurokinin-mediated mechanisms in fear and anxiety (Q30445747) (← links)
- Effects of substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear-potentiated startle (Q30448437) (← links)
- The role of substance P in depression: therapeutic implications (Q30473429) (← links)
- Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils (Q30479172) (← links)
- Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia (Q30621023) (← links)
- Rett syndrome: review of biological abnormalities. (Q30639662) (← links)
- Are child-, adolescent-, and adult-onset depression one and the same disorder? (Q30655315) (← links)
- Investigation of the metabolism of substance P at the blood-brain barrier using capillary electrophoresis with laser-induced fluorescence detection (Q30667130) (← links)
- Bayesian probability of success for clinical trials using historical data (Q30863734) (← links)
- Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. (Q30957945) (← links)
- Identification of multiple urechistachykinin peptides, gene expression, pharmacological activity, and detection using mass spectrometric analyses (Q30978170) (← links)
- On the feasibility of designing new antidepressants (Q31116056) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder (Q31121208) (← links)
- Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study (Q31416033) (← links)
- Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist (Q31882725) (← links)
- Substance P: a pioneer amongst neuropeptides (Q31901693) (← links)